Mitoxana (Ifosfamide)

Ifosfamide is an alkylating agent that is metabolised in the liver to active compounds which bind to DNA. This binding creates cross‑links that block DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells.

The dosing schedule for Mitoxana is individualized by the treating oncologist based on the specific cancer type, stage, patient weight, renal function and concurrent therapies. Only a qualified prescriber can determine the appropriate dose and infusion frequency.

Ifosfamide is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To order Mitoxana, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mitoxana (ifosfamide) shares a similar mechanism with other alkylating agents such as cyclophosphamide, but it has a distinct metabolic activation pathway and a higher propensity for hemorrhagic cystitis, requiring routine use of the protective agent mesna. Choice of agent depends on tumour type, prior therapy and toxicity profile.

Mitoxana should be stored at controlled room temperature, typically below 25 °C, in its original packaging. The product must be protected from light, moisture and extreme temperatures to maintain stability until reconstitution for intravenous administration.

Mitoxana is supplied as an injectable solution that is reconstituted and administered intravenously by a qualified healthcare professional. The infusion is usually given over a period of 1–3 hours, with appropriate pre‑hydration and concomitant mesna to reduce bladder toxicity.

The most serious risks include severe nephrotoxicity, neurotoxicity (including seizures and encephalopathy), profound myelosuppression leading to infection or bleeding, and hemorrhagic cystitis. Patients should be closely monitored for renal function, neurological status and blood counts throughout therapy.

Mitoxana is contraindicated in patients with known hypersensitivity to ifosfamide or its excipients, those with severe renal impairment, uncontrolled infections, or pre‑existing severe neuro‑psychiatric disorders. Caution is also advised for patients with a history of bladder disease.